Vanguard Group Inc Lineage Cell Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LCTX
# of Institutions
123Shares Held
94.4MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$34.6 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$7.93 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$4.15 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$3.9 Million0.44% of portfolio
-
Raffles Associates LP New York, NY4.36MShares$3.62 Million5.55% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $141M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...